SpringWorks fixes ‘minor data handling error’ after March Form 483 for trial site linked to upcoming PDUFA
The FDA issued SpringWorks Therapeutics a Form 483 on March 31, saying that the company’s own clinical trial protocols were not followed.
But SpringWorks COO Badreddin Edris told Endpoints News in a phone interview on Monday that “it was a minor data handling error on an exploratory endpoint that was corrected within a week in March and resulted in no impact on the data” that formed the basis of the company’s application for its first “pipeline-in-a-product” oncology treatment, the oral gamma secretase inhibitor, dubbed nirogacestat, or Ogsiveo.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.